In patients with HF, a meta-analysis including 16 RCTs, therapy with an SGLT2-i, determined a statistically significant reduction in SBP from a baseline of −1.68 mmHg (95% CI −2.70; −0.66; p = 0.001) vs. control [83]. This evidence concerns the gene SLC5A2 and hydrops fetalis.